Study to Evaluate the Efficacy, Safety, and Tolerability of Efzofitimod in Patients With Systemic Sclerosis (SSc)-Related Interstitial Lung Disease (ILD) (SSc-ILD)
Conditions
Interstitial Lung Disease
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
aTyr Investigative Site, Los Angeles, California, United States
aTyr Investigative Site, San Diego, California, United States
aTyr Investigative Site, Miami, Florida, United States
aTyr Investigative Site, Chicago, Illinois, United States
aTyr Investigative Site, Chicago, Illinois, United States
aTyr Investigative Site, Chicago, Illinois, United States
aTyr Investigative Site, New Orleans, Louisiana, United States
aTyr Investigative Site, New York, New York, United States
aTyr Investigative Site, Cleveland, Ohio, United States
aTyr Investigative Site, Oklahoma City, Oklahoma, United States
aTyr Investigative Site, Charleston, South Carolina, United States
aTyr Investigative Site, Dallas, Texas, United States
aTyr Investigative Site, Houston, Texas, United States
aTyr Investigative Site, Salt Lake City, Utah, United States
aTyr Investigative Site, Richmond, Virginia, United States
Study leads
Lisa Carey
Study Director
aTyr Pharma, Inc.